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Cardiovascular disease after renal transplantation. Cardiovas- and they occur at least twice as often as in the back-
cular disease is a major hazard limiting the life expectancy of ground population [2–6].
renal transplant recipients and the most frequent cause of late In the cyclosporine era, with improving success ofallograft loss. Patients with renal disease have usually been
transplantation, death with graft function emerged asexposed for both traditional, and for them unique, risk factors
the leading cause of graft loss after the first year, and itover a prolonged period of time and may carry the burden of
advanced atherosclerotic disease already at the time of trans- accounts for the majority of graft losses [3, 5]. Of deaths
plantation. The observed survival benefit of transplantation is with a functioning graft, more than half are from ischemic
probably from elimination of the numerous uremia-related risk heart disease (IHD) and other vascular diseases [3]. Thefactors. However, immunosuppressive therapy and the chronic
risk of death from IHD was found to be 6.4 times higherinflammatory state, together with genetic susceptibility and not
in non-diabetic and 20.8 times higher in diabetic RTRsinfrequently impaired renal function, may bring about new
potentially atherogenic conditions. Metabolic risk factors may aged 55–64 years compared with the general population
jeopardize both patient and graft survival. Several observa- [3]. The risk for angina pectoris was increased 12–16 times
tional studies provide evidence for the negative impact of pre- in RTRs aged 40–49 years and 3–4 times in those agedexisting metabolic abnormalities on long-term outcomes. Iden-
60–69 years [7]. Thus, CVD is a major threat to RTRs.tification of modifiable cardiovascular risk factors may enable
risk reduction also in renal transplant recipients. Results of
ongoing intervention trials are awaited. The observed improve-
RISK FACTORS FOR CVD IN RTRSment of patient survival after renal transplantation during the
past decade may reflect the increasing awareness and more The established risk factors for atherosclerotic vascu-
optimal care of patients throughout the course of renal disease. lar disease in the general population are present in RTRs
and are probably also involved in the progression of
renal disease [8]. The underlying renal disease resulting
Cardiovascular disease (CVD) is the leading cause of in ESRD is frequently a consequence of a disorder lead-
morbidity and mortality both in patients with chronic ing to atherosclerotic vascular disease per se, when renal
renal disease and after successful renal transplantation. disease is part or a consequence of this condition (e.g.,
The burden of CVD exceeds by far that of the general diabetes, hypertensive nephrosclerosis). In addition, pa-
population. Many of the traditional CVD risk factors tients with renal disease have several other abnormalities
are operative in renal transplant recipients (RTRs). In that are consequences of renal disease and impaired re-
addition, several features unique to RTRs deserve spe- nal function and which, in turn, may contribute to the
cific attention. development and progression of CVD. Furthermore, phar-
macotherapy after transplantation may exert potential
adverse effects on CVD manifestations. So, the preexist-EPIDEMIOLOGY OF CVD FOLLOWING
ing and, to a various extent, persisting or recurring renalRENAL TRANSPLANTATION
failure, proteinuria, ongoing inflammation, infections,In spite of the substantial survival benefit of renal trans-
immunosuppressive, and other therapy will modify theplantation over long-term dialysis [1], transplant recipi-
effect of traditional risk factors for CVD. Indeed, recentents have about four times higher mortality after the
studies emphasize that the high incidence of IHD is un-first year compared with the general population [2]. CVD
derestimated by the risk factors identified in the generalevents represent the single most frequent cause of death
population [9].in RTRs accounting for 35–50% of all-cause mortality,
Traditional risk factors
Predictors for CVD in the general population includeKey words: cardiovascular disease, renal transplantation, hyperlipid-
emia, metabolic risk factors, hyperhomocysteinemia. non-modifiable factors such as age, gender, genetic back-
ground, and also numerous risk factors, which are more 2002 by the International Society of Nephrology
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or less modifiable by lifestyle changes and pharmacother- azathioprine treatment [20] is caused by an inhibitory
effect of azathioprine on lp(a) metabolism [19].apy. Among the modifiable risk factors, obesity, smoking,
hypertension, diabetes, hyperlipidemia, and hyperhomo- Several large studies with long follow-up before the
statin era (see below) accounted for independent associ-cysteinemia are best delineated. With better understand-
ing of the pathogenic role of these risk factors and evolu- ation between lipid abnormalities, CVD, and mortality.
For example, Kasiske found that hypercholesterolemiation of potent therapeutic agents with moderate side
effects, effective modification of cardiovascular risk fac- correlated with posttransplant vascular disease [21]. In
a subsequent study, however, only HDL levels amongtors and reduction of CVD morbidity and mortality can
be achieved in the general population [10]. This article lipid variables were independently associated with IHD
[22]. Still, the risk for major IHD after the first year waswill focus on some modifiable risk factors for CVD in
renal transplant recipients. increased twofold for patients with serum cholesterol
200 mg/dL or triglycerides350 mg/dL [9]. Aker found
a relative risk of 2.3 for post-transplant CVD associated
LIPID AND LIPOPROTEIN ABNORMALITIES
with LDL cholesterol180 mg/dL [23]. Aakhus reported
IN RTRS
independent association between IHD and total choles-
Renal disease is associated with profound abnormali- terol [7]. Roodnat showed in a retrospective study with
ties in lipid and lipoprotein metabolism [11]. In RTRs, over five years of follow-up that serum total cholesterol
hyperlipidemia is a well-known feature. Factors with in- at one year was a significant independent predictor in-
fluence on post-transplant hyperlipidemia include age, fluencing all end points, including patient survival [24].
body weight, pretransplant lipid levels, and, not unex- So far, there is no evidence that lipid lowering reduces
pectedly, presence of proteinuria and allograft dysfunc- the burden of CVD in RTRs. Several options are avail-
tion. Immunosuppressive agents, in particular corticoste- able for intervention. Tailoring immunosuppression with
roids and cyclosporine, are important contributory factors corticosteroid or cyclosporine withdrawal or avoidance and
[12]. Elevated total and LDL cholesterol occur in about treatment with HMG-CoA reductase inhibitors (statins)
60% and hypertriglyceridemia in about 35%, whereas will improve lipid abnormalities [12, 16]. Statins are
low HDL cholesterol is only present in 15% of RTRs widely used and their effects beyond lowering total and
[11]. In prospective studies, the time-dependent changes LDL cholesterol levels nominate them as an attractive
in cyclosporine- and prednisolon-treated patients are char- alternative. Results of an ongoing, large, controlled flu-
acterized by an increase in total, LDL, and HDL choles- vastatin trial are awaited.
terol while triglycerides remain unchanged [13, 14]. The
lipoprotein profile may still become more atherogenic
THE DIABETIC TRANSPLANT RECIPIENTwith triglyceride-rich small, dense LDL, susceptible for
oxidation [12]. Enhanced LDL oxidation is indicated by Diabetes is the most common disease leading to ESRD
in all Western countries. Diabetic nephropathy is associ-several studies and, of additional concern, both cyclo-
sporine and tacrolimus have been implicated to increase ated with excess CVD morbidity and mortality at all
stages of the disease. Diabetic patients manifest the high-LDL oxidation [15]. Tacrolimus, however, appears to
have less negative impact on the lipid pattern [16]. Siro- est mortality rate of any group of ESRD patients. Among
patients starting dialysis, diabetics present more oftenlimus, on the other hand, is well known for its propen-
sity to cause hyperlipidemia, in particular hypertriglyc- with clinically diagnosed IHD [25]. Even in asymptotic
diabetic transplant candidates, coronary angiographyeridemia [17].
Lipoprotein(a), lp(a), is a risk factor for atheroscle- can reveal coronary artery stenosis 50% in more than
half of them [26]. Importantly, a pathologic coronaryrotic vascular disease in the general population. Its spe-
cific apoprotein, apo(a), shows structural homology with angiography may predict major adverse cardiovascular
events after transplantation [26]. The survival benefit ofplasminogen and lp(a) can inhibit fibrinolysis. The size
of apo(a) is genetically determined, and elevation of renal transplantation over dialysis is especially valid for
diabetic transplant recipients [1]. Therefore, it is advo-lp(a) plasma levels shows an inverse relationship with
apo(a) isoform size. Lp(a) is often elevated in patients cated that renal transplantation should be the first thera-
peutic choice for all suitable diabetic ESRD patients.with renal disease [18]. Cross-sectional studies in RTRs
yielded conflicting results, but prospective studies dem- Diabetic RTRs are, however, at further increased CVD
risk compared with non-diabetics. For example, Lind-onstrate a decrease in lp(a) levels following transplanta-
tion [15, 19]. The decrease in lp(a) depends on apo(a) holm reported a twofold higher risk of death from IHD
in diabetic RTRs compared with non-diabetics (25% vs.phenotype, and pretransplant lp(a) levels, and is influ-
enced by allograft function and proteinuria [19]. It is 11.4%) [3]. Arend found a 2.9 relative risk of mortality
after the first year in diabetics [2]. Registry data fromalso advocated that the previously reported elevation
of lp(a) in cyclosporine-treated patients compared with the United States account also for more than two-fold
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higher than average risk of death from CVD in diabetic tolerance/diabetes, lipid abnormalities with hypertriglyc-
eridemia and low HDL cholesterol levels, and defectRTRs [5]. Aker reported a 4.3 times increased risk of
post-transplant CVD in diabetics. [23]. Aakhus found fibrinolysis have strong correlation with atherosclerotic
vascular disease in the general population. Insulin resis-IHD in 24% of diabetics versus 12% of non-diabetics
[7]. In Kasiske’s study, diabetic RTRs had a more than tance and similar lipid abnormalities are present in renal
failure. After transplantation, immunosuppressive ther-threefold increased risk for IHD and for cerebrovascular
disease and a 28-fold risk for peripheral vascular disease apy, in particular corticosteroids, may further aggravate
these metabolic abnormalities.[22]. The relative risk for IHD associated with diabetes
was three- to five-fold increased in a subsequent study
Obesity[9]. Importantly, recent reports indicate that simultane-
Obesity has long been recognized as a significant riskous pancreas-kidney transplantation reduces excess mor-
factor for CVD in the general population, mainly fromtality in type 1 diabetic RTRs [27–29]. In addition, CVD
induction of other risk factors such as hypertension, insu-mortality and left ventricular function will improve after
lin resistance, and associated metabolic abnormalitiessuccessful pancreas transplantation [29]. Restoring nor-
[35]. Few ESRD patients are obese; the pretransplantmoglycemia may be the most significant factor for im-
frequency is 14–26% depending on definition [32, 23,proved outcomes.
36]. Weight gain of more than 10% after transplantation
occurs in almost two thirds of patients, is influenced by
POST-TRANSPLANT HYPERTENSION demographic factors, and associated with increase in
Hypertension is one of the most powerful predictors both serum cholesterol and triglyceride levels [36]. The
for CVD in the general population and is frequently prevalence of obesity is between 28% and 48% 1–2 years
associated with other CVD risk factors. Patients with after transplantation [23, 32, 36]. Obese RTRs are at in-
renal disease have 60–100% prevalence of hypertension creased risk of adverse outcomes. Postoperative complica-
[10]. Pretransplant hypertension is a strong predictor of tions are more common, and the risk to develop post-
post-transplant hypertension. Several other contributory transplant diabetes mellitus (PTDM) is increased (12%
factors are recognized [30]. Genetic factors may also vs. 2%) [37]. Obesity with body mass index (BMI) 30
have an impact [31]. The prevalence increased from 50% kg/m2 was also found to be associated with reduced pa-
to 70–90% in the cyclosporine era [30, 32]. Corticoste- tient survival and increased prevalence of IHD [37].
roids account for 15% of it [33], and steroid withdrawal Moderate obesity (BMI 25 kg/m2) was also associated
ameliorates hypertension [16]. Tacrolimus and cyclo- with a 2–3 fold increased risk of CVD [23] and a twofold
sporine seem to have similar adverse impact on blood pres- increased risk for graft loss and death [38].
sure in RTRs [16]. Ambulatory blood pressure monitor-
Impaired glucose tolerance (IGT) and PTDMing may reveal a disturbed diurnal variation (non-dipper
The diabetogenic effect of corticosteroid therapy ispattern), which was found to occur in 94.5% of patients
well established and is principally mediated by inductionwith chronic allograft nephropathy [34]. Post-transplant
of insulin resistance [39]. Both cyclosporine and tacroli-hypertension may be associated with hyperlipidemia,
mus have adverse impact on insulin and glucose metabo-IHD, and allograft failure and is also a significant inde-
lism, with tacrolimus possibly being more diabetogenic,pendent risk factor for CVD [7].
especially in certain patient populations [16, 39]. InsulinTreatment of hypertension should be aggressive with
resistance and impaired glucose tolerance (IGT) is oftentarget blood pressure below 130/80 [10, 30]. Several stud-
present in RTRs [32, 40]. When insulin resistance is asso-ies have shown that CCBs may protect from cyclosporine
ciated with impaired insulin secretion, PTDM will de-nephrotoxicity [30]. On the other hand, one recent study
velop [40]. At 10 weeks after transplantation 52% offound adverse impact on IHD risk of dihydropyridine
patients had glucose intolerance, including those withCCBs [9]. Patients with proteinuria would benefit more
PTDM [40]. Age, heredity, corticosteroid dose, hypertri-by treatment with angiotensin-converting enzyme inhibi-
glyceridemia, elevated apoB and 2-hour insulin levelstors (ACE-Is) or angiotensin receptor antagonists. ACE-Is
were all independently associated with these abnormali-may have additional beneficial effects by reducing post-
ties, thus linking IGT and PTDM to the metabolic syn-transplant erythrocytosis. The cardioprotective proper-
drome [40].ties of -blockers should be weighed against possible
The frequency of PTDM in the cyclosporine era isadverse metabolic consequences [30].
8–18%, with manifestation most frequently reported
during the first 3 post-transplant months [39]. According
METABOLIC RISK FACTOR SYNDROME to a recent report, the risk of PTDM may increase contin-
Features of the metabolic risk factor syndrome [35] with uously with time after transplantation, and the preva-
lence has almost doubled since 1995 (5.9 vs. 10.5% atobesity, hypertension, insulin resistance/impaired glucose
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1 yr and 8.8 vs. 16.9% at 3 yrs) [41]. It is estimated that of CVD and mortality in kidney transplanted smokers
steroids are responsible for 10%, and cyclosporine for [2, 23, 48, 49]. Smoking had similar negative impact on
an additional 5% [33]. Similar to IGT, older age, higher patient survival as diabetes [48]. Heavy smokers (25
steroid doses, and a positive family history of diabetes pack-years) at the time of transplantation had 1.42 rela-
are established risk factors for PTDM [39]. PTDM is tive risk for post-transplant mortality and 2.14 relative
associated with a more than twofold increased relative risk for CVD [49]. There was no adverse effect of smok-
risk of IHD, and also with higher post-transplant choles- ing among patients who quitted more than 5 years before
terol and triglyceride and lower HDL levels, further ma- transplantation [49]. Smoking cessation is highly recom-
jor predictors of IHD [22]. The adverse impact of PTDM mended for patients with renal disease.
on patient survival is, however, not equally evident at
different centers. For example Miles reported 12-year
RENAL DISEASE/UREMIA-ASSOCIATEDsurvival of PTDM patients similar to controls (71% vs.
RISK FACTORS74%) [42]. Revanur found inferior 10-year survival of
PTDM patients compared with non-diabetics (49% vs. Homocysteine
75%) [43]. Only patients younger than 55 years ac-
Moderate hyperhomocysteinemia is an independentcounted for this survival difference, and for them, PTDM
predictor of atherosclerotic vascular disease in the gen-was associated with 2.54 times higher risk of death [43].
eral population. In renal failure, hyperhomocysteinemiaSimilar to lipid abnormalities, management of PTDM
develops in parallel with the degree of decreasing GFRmay include modification of immunosuppression with suc-
[50]. After renal transplantation, total homocysteine (tHcy)cessive withdrawal or avoidance of corticosteroids and
levels decrease but do not normalize [51]. Whether cyclo-calcineurin inhibitors, strategies with well-documented
sporine therapy contributes to elevated post-transplantbeneficial metabolic consequences [39]. Achievement of
tHcy levels is controversial [50–53]. Tacrolimus-treatedoptimal metabolic control with oral hypoglycemic agents
patients were not found to have independent differenceand if necessary with insulin therapy, albeit not docu-
in tHcy levels compared with those treated with cyclo-mented in RTR, is probably as important as in non-
sporine [54]. Association of elevated PAI-1 activity andtransplanted diabetic patients [39].
homocysteine levels is of interest, linking hyperhomocys-
Fibrinolysis teinemia to defect fibrinolysis and the metabolic syn-
drome [55]. Increased tHcy levels are present in 5,10-Impaired fibrinolysis is associated with increased car-
methylenetetrahydrofolate reductase (MTHFR) genediovascular morbidity. PAI-1 is the specific inhibitor of
polymorphism (677 C  T). However, the TT genotypethe fibrinolytic system, and elevated levels of PAI-1 are
associated with impaired fibrinolysis, increased risk of is not over-represented in RTRs [55].
thrombosis, and CVD in the general population. Ele- Hyperhomocysteinemia is linked to an almost three-
vated PAI-1 levels are coupled with other features of fold risk of de novo or recurrent CVD in ESRD and sug-
the metabolic risk factor syndrome such as obesity, hy- gested as a risk factor for CVD in RTRs by several studies
pertriglyceridemia, and hyperinsulinemia and non-insu- [56]. Recently, tHcy was found to be associated with a
lin dependent diabetes, thus linking defective fibrinolysis relative risk of 1.06 for CVD [52]. Notably, s-creatinine
to the insulin resistance syndrome. Impaired fibrinolysis levels were also independently related to CVD events
and elevated PAI-1 activity are frequently observed in (1.34 relative risk) and were also the major determinants
RTRs [32, 44, 45]. Both corticosteroids [44] and cyclo- of tHcy levels. The importance of serum creatinine as
sporine [45] are suggested contributors. Hypercholes- the major independent determinant of plasma tHcy level
terolemia, obesity, and steroid-induced diabetes could is underlined by a recent study [53]. Two other studies
be identified as risk factors for elevated plasma PAI-1 could not find any association between hyperhomocys-
activity in cyclosporine-treated patients [45]. Conversion teinemia and patient or graft survival [57, 58].
from cyclosporine to azathioprine as well as steroid with- Folic acid supplementation in pharmacological dose,
drawal resulted in improved fibrinolysis and decrease in preferably complemented with B6 and B12 vitamins, canPAI-1 levels [46, 47]. Presence of impaired fibrinolysis
effectively reduce the hyperhomocysteinemia of RTRs
together with all other features of the metabolic syn-
[54, 56]. This decrease seems to be influenced by thedrome six months after transplantation was associated
MTHFR genotype, as patients with the 677TT genotypewith poor outcome [32].
reduce tHcy levels most. Furthermore, elevated PAI-1
levels also decreased after 2 months of therapy [55]. The
SMOKING potential beneficial effect of vitamin supplementation on
patient and/or graft survival and on CVD events in RTRsSmoking increases the risk for CVD in the general
population. Several studies demonstrated increased risk remains to be demonstrated.
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Proteinuria dent risk factor for increased mortality after transplanta-
tion in the United States [67].Proteinuria is a risk factor not only for progressive
renal disease but also for CVD [8]. In RTRs, both early
and late proteinuria predicts adverse outcome [59, 60]. SUMMARY
Proteinuria one year after transplantation occurred dur- Cardiovascular disease after renal transplantation is
ing a follow-up of at least five years associated with a major challenge. As the accelerated atherosclerotic
twofold increased risk of death [60]. vascular disease starts during the early phase of chronic
renal disease and has a propensity to progress rapidlyLeft ventricular hypertrophy and dysfunction
during dialysis therapy, efforts have to concentrate on
LVH is present in the majority of patients starting reducing CVD risk factors at all stages of renal disease.
renal replacement therapy and is associated with adverse During the past decade, substantial improvement of pa-
outcome. Risk factors for LVH include anemia, hyper- tient survival after renal transplantation was observed
tension, hypoalbuminemia, ischemic heart disease, and [5, 6]. To further improve the outcome for RTRs, aware-
volume overload. [10, 61]. Time on dialysis may also ness of the potential hazards associated with CVD risk
influence LVH [62]. Renal transplantation leads to re- factors and therapeutic measures to reduce modifiable
gression of LVH paralleling blood pressure improve- risk factors, and thereby the incidence and consequences
ment [61]. LVH regression was found to continue during of CVD, are advocated.
the first two years, and it remained unchanged up to
Reprint requests to Emo¨ke M. Dime´ny, M.D., Ph.D., Division offour years after renal transplantation [63]. Older age and
Nephrology, Department of Medicine, University Hospital, S-901 85hypertension may retard this process [63]. The ACE-DD Umea˚, Sweden.
genotype also favors LVH in RTRs, and these patients E-mail: emoke.dimeny@vll.se
will, as expected, benefit more from ACE-inhibitors,
independent of blood pressure control [64]. Neverthe- REFERENCES
less, in a double-blind randomized trial with equally well- 1. Wolfe RA, Ashby VB, Milford EL, et al: Comparison of mortality
controlled blood pressure, the effect on LVH reduction in all patients on dialysis, patients on dialysis awaiting transplanta-
tion, and recipients of a first cadaveric transplant. N Engl J Medwas similar in hypertensive RTRs treated with the
341:1725–1730, 1999
ACE-I lisinopril or a CCB, controlled release nifedipine 2. Arend SM, Mallat MJ, Westendorp RJ, et al: Patient survival
after renal transplantation; more than 25 years follow-up. Nephrol[65]. The presence of LVH, as well as ventricular dilata-
Dial Transplant 12:1672–1679, 1997tion and poor systolic function before transplantation,
3. Lindholm A, Albrechtsen D, Frodin L, et al: Ischemic heart
predicted increased mortality after renal transplantation disease–major cause of death and graft loss after renal transplanta-
tion in Scandinavia. Transplantation 60:451–457, 1995during a median follow up of 7.5 years, while other,
4. Foley RN, Parfrey PS, Sarnak MJ: Epidemiology of cardiovascu-traditional risk factors such as hypertension, hyperlipid-
lar disease in chronic renal disease. J Am Soc Nephrol 9(Suppl 12):
emia and smoking did not. Subsequently, on echocardi- S16–S23, 1998
5. Ojo AO, Hanson JA, Wolfe RA, et al: Long-term survival inography performed 4 months after transplantation, only
renal transplant recipients with graft function. Kidney Int 57:307–LVH provided a stronger association with adverse out- 313, 2000
come during follow-up [66]. Prevention of the develop- 6. van Dijk PCW, Jager KJ, de Charro F, et al: Renal replacement
therapy in Europe: The results of a collaborative effort by thement of LVH by optimal treatment of hypertension,
ERA–EDTA registry and six national or regional registries.preferably with ACE inhibitors throughout the course Nephrol Dial Transplant 16:1120–1129, 2001
of renal disease [61], control of renal anemia and volume 7. Aakhus S, Dahl K, Wideroe TE: Cardiovascular morbidity and
risk factors in renal transplant patients. Nephrol Dial Transplantoverload may be beneficial for reducing CVD also after
14:648–654, 1999renal transplantation. 8. Sarnak MJ, Levey AS: Cardiovascular disease and chronic re-
nal disease: A new paradigm. Am J Kidney Dis 35(Suppl 1):S117–
Time on dialysis S131, 2000
9. Kasiske BL, Chakkera HA, Roel J: Explained and unexplainedCVD has a propensity to accelerated progression dur- ischemic heart disease risk after renal transplantation. J Am Soc
ing the years on dialysis, particularly in diabetic patients. Nephrol 11:1735–1743, 2000
10. Levey AS, Beto JA, Coronado BE, et al: Controlling the epidemicPretransplant vascular disease is one of the strongest
of cardiovascular disease in chronic renal disease: What do wepredictors of post-transplant CVD [21]. Thus, it could know? What do we need to learn? Where do we go from here?
be expected that the length of prior dialysis therapy National Kidney Foundation Task Force on Cardiovascular Dis-
ease. Am J Kidney Dis 32:853–906, 1998would also have a negative impact on CVD morbidity
11. Kasiske BL: Hyperlipidemia in patients with chronic renal disease.and mortality after renal transplantation. Indeed, time Am J Kidney Dis 32(Suppl 3):S142–S156, 1998
on dialysis had a strong negative influence on patient 12. Massy ZA, Kasiske BL: Post-transplant hyperlipidemia: Mecha-
nisms and management. J Am Soc Nephrol 7:971–977, 1996survival after transplantation in some [62] but not all
13. Dime´ny E, Wahlberg J, Lithell H, Fellstro¨m B: Hyperlipidemia
studies [2]. Registry data reveal, however, that waiting in renal transplantation-risk factor for long-term graft outcome.
Eur J Clin Invest 25:574–583, 1995time, in a dose-dependent manner, is a strong indepen-
Dimeny: Cardiovascular risk in renal transplantation S-83
14. Schena A, Di Paolo S, Morrone LF, et al: Are lipid-dependent 40. Hjelmesaeth J, Hartmann A, Midtvedt K, et al: Metabolic cardio-
indicators of cardiovascular risk affected by renal transplantation? vascular syndrome after renal transplantation. Nephrol Dial Trans-
Clin Transplant 14:139–146, 2000 plant 16:1047–1052, 2001
15. Varghese Z, Fernando RL, Turakhia G, et al: Calcineurin inhibi- 41. Cosio FG, Pesavento TE, Osei K, et al: Post-transplant diabetes
tors enhance low-density lipoprotein oxidation in transplant pa- mellitus: Increasing incidence in renal allograft recipients trans-
tients. Kidney Int 56(Suppl 71):S137–S140, 1999 planted in recent years. Kidney Int 59:732–737, 2001
16. Henry ML: Cyclosporine and tacrolimus (FK506): A comparison 42. Miles AM, Sumrani N, Horowitz R, et al: Diabetes mellitus after
of efficacy and safety profiles. Clin Transplant 13:209–220, 1999 renal transplantation: As deleterious as non-transplant-associated
17. Brattstrom C, Wilczek H, Tyden G, et al: Hyperlipidemia in diabetes? Transplantation 65:380–384, 1998
renal transplant recipients treated with sirolimus (rapamycin). 43. Revanur VK, Jardine AG, Kingsmore DB, et al: Influence of
Transplantation 65:1272–1274, 1998 diabetes mellitus on patient and graft survival in recipients of
18. Kronenberg F, Utermann G, Dieplinger H: Lipoprotein(a) in kidney transplantation. Clin Transplant 15:89–94, 2001
renal disease. Am J Kidney Dis 27:1–25, 1996 44. Patrassi GM, Sartori MT, Rigotti P, et al: Reduced fibrinolytic
19. Kerschdorfer L, Konig P, Neyer U, et al: Lipoprotein(a) plasma potential one year after kidney transplantation: Relationship to
concentrations after renal transplantation: A prospective evalua- long-term steroid treatment. Transplantation 59:1416–1420, 1995
tion after 4 years of follow-up. Atherosclerosis 144:381–391, 1999 45. Verpooten GA, Cools FJ, van der Planken MG, et al: Elevated
20. Webb AT, Reaveley DA, O’Donell M, et al: Does cyclosporin plasminogen activator inhibitor levels in cyclosporin-treated renal
increase lipoprotein(a) concentrations in renal transplant recipi- allograft recipients. Nephrol Dial Transplant 11:347–351, 1996
ents? Lancet 341:268–270, 1993 46. van den Dorpel MA, Veld AJ, Levi M, et al: Beneficial effects
21. Kasiske BL: Risk factors for accelerated atherosclerosis in renal of conversion from cyclosporine fibrinolysis in renal transplant
transplant recipients. Am J Med 84:985–992, 1988 recipients. Arterioscler Thromb Vasc Biol 19:1555–1558, 1999
22. Kasiske BL, Guijarro C, Massy ZA, et al: Cardiovascular disease 47. Sartori MT, Patrassi GM, Rigotti P, et al: Improved fibrinolytic
after renal transplantation. J Am Soc Nephrol 7:158–165, 1996 capacity after withdrawal of steroid immunosuppression in renal
23. Aker S, Ivens K, Grabensee B, Heering P: Cardiovascular risk transplant recipients. Transplantation 69:2116–2121, 2000
factors and diseases after renal transplantation. Int Urol Nephrol 48. Cosio FG, Falkenhain ME, Pesavento TE, et al: Patient survival
30:777–788, 1998 after renal transplantation: II. The impact of smoking. Clin Trans-
24. Roodnat JI, Mulder PG, Zietse R, et al: Cholesterol as an inde- plant 13:336–341, 1999
pendent predictor of outcome after renal transplantation. Trans- 49. Kasiske BL, Klinger D: Cigarette smoking in renal transplant
plantation 69:1704–1710, 2000 recipients. J Am Soc Nephrol 11:753–759, 2000
25. Foley RN, Culleton BF, Parfrey PS, et al: Cardiac disease in 50. Arnadottir M, Hultberg B, Vladov V, et al: Hyperhomocysteine-
diabetic end-stage renal disease. Diabetologia 40:1307–1312, 1997 mia in cyclosporine-treated renal transplant recipients. Trans-
26. Manske CL, Wilson RF, Wang Y, Thomas W: Atherosclerotic plantation 61:509–512, 1996
vascular complications in diabetic transplant candidates. Am J 51. Arnadottir M, Hultberg B, Wahlberg J, et al: Serum total homo-
Kidney Dis 29:601–607, 1997 cysteine concentration before and after renal transplantation. Kid-27. Tyden G, Tollemar J, Bolinder J: Combined pancreas and kidney ney Int 54:1380–1384, 1998transplantation improves survival in patients with end-stage dia-
52. Ducloux D, Motte G, Challier B, et al: Serum total homocysteinebetic nephropathy. Clin Transplant 14:505–508, 2000
and cardiovascular disease occurrence in chronic, stable renal28. Becker BN, Brazy PC, Becker YT, et al: Simultaneous pan-
transplant recipients: A prospective study. J Am Soc Nephrolcreas-kidney transplantation reduces excess mortality in type 1
11:134–137, 2000diabetic patients with end-stage renal disease. Kidney Int 57:2129–
53. Bostom AG, Kronenberg F, Gohh RY, et al: Chronic renal trans-2135, 2000
plantation: A model for the hyperhomocysteinemia of renal insuf-29. La Rocca E, Fiorina P, di Carlo V, et al: Cardiovascular outcomes
ficiency. Atherosclerosis 156:227–230, 2001after kidney-pancreas and kidney-alone transplantation. Kidney
54. Fernandez-Miranda C, Gomez P, Diaz-Rubio P, et al: PlasmaInt 60:1964–1971, 2001
homocysteine levels in renal transplanted patients on cyclosporine30. Midtvedt K, Neumayer HH: Management strategies for posttrans-
or tacrolimus therapy: Effect of treatment with folic acid. Clinplant hypertension. Transplantation 70(Suppl 11):S64–S69, 2000
Transplant 14:110–114, 200031. Abdi R, Tran TB, Zee R, et al: Angiotensin gene polymorphism
55. Marcucci R, Fedi S, Brunelli T, et al: High cysteine levels in renalas a determinant of posttransplantation renal dysfunction and hy-
transplant recipients: relationship with hyperhomocysteinemia andpertension. Transplantation 72:726–729, 2001
5,10-MTHFR polymorphism. Transplantation 71:746–751, 200132. Dimeny E, Fellstrom B: Metabolic abnormalities in renal trans-
56. Bostom AG: Homocysteine: “Expensive creatinine” or important,plant recipients: Risk factors and predictors of chronic graft dys-
modifiable risk factor for arteriosclerotic outcomes in renal trans-function? Nephrol Dial Transplant 12:21–24, 1997
plant recipients? J Am Soc Nephrol 11:149–151, 200033. Veenstra DL, Best JH, Hornberger J, et al: Incidence and long-
57. Dimeny E, Hultberg B, Wahlberg J, et al: Serum total homocys-term cost of steroid-related side effects after renal transplantation.
teine concentration does not predict outcome in renal transplantAm J Kidney Dis 33:829–839, 1999
recipients. Clin Transplant 12:563–568, 199834. Kooman JP, Christiaans MH, Boots JM, et al: A comparison
58. Hagen W, Fodinger M, Heinz G, et al: Effect of MTHFRbetween office and ambulatory blood pressure measurements in
genotypes and hyperhomocysteinemia on patient and graft sur-renal transplant patients with chronic transplant nephropathy. Am
vival in kidney transplant recipients. Kidney Int 59(Suppl 78):S253–J Kidney Dis 37:1170–1176, 2001
S257, 200135. Reaven GM: Role of insulin resistance in human disease. Diabetes
59. Perez-Fontan M, Rodriguez-Carmona A, Garcia Falcon T,37:1595–1607, 1988
Valdes F: Early proteinuria in renal transplant recipients treated36. Johnson CP, Gallagher-Lepak S, Zhu YR, et al: Factors influenc-
with cyclosporin. Transplantation 67:561–568, 1999ing weight gain after renal transplantation. Transplantation 56:822–
60. Roodnat JI, Mulder PG, Rischen-Vos J, et al: Proteinuria after827, 1993
renal transplantation affects not only graft survival but also patient37. Modlin CS, Flechner SM, Goormastic M, et al: Should obese
survival. Transplantation 72:438–444, 2001patients lose weight before receiving a kidney transplant? Trans-
61. Jardin AG: Pretransplant management of end-stage renal diseaseplantation 64:599–604, 1997
patients to minimize posttransplant risk. Transplantation 70(Suppl38. Meier-Kriesche HU, Vaghela M, Thambuganipalle R, et al: The
11):S46–S50, 2000effect of body mass index on long-term renal allograft survival.
62. Cosio FG, Alamir A, Yim S, et al: Patient survival after renalTransplantation 68:1294–1297, 1999
transplantation: I. The impact of dialysis pre-transplant. Kidney39. Jindal RM, Hjelmesaeth J: Impact and management of post-
Int 53:767–772, 1998transplant diabetes mellitus. Transplantation 70(Suppl 11):S58–
S63, 2000 63. Rigatto C, Foley RN, Kent GM, et al: Long-term changes in left
Dimeny: Cardiovascular risk in renal transplantationS-84
ventricular hypertrophy after renal transplantation. Transplanta- transplant recipients: A prospective randomized double-blind
study. Transplantation 72:107–111, 2001tion 70:570–575, 2000
64. Hernandez D, Lacalzada J, Salido E, et al: Regression of left 66. McGregor E, Stewart G, Rodger RS, Jardine AG: Early echo-
cardiographic changes and survival following renal transplantation.ventricular hypertrophy by lisinopril after renal transplantation:
Role of ACE gene polymorphism. Kidney Int 58:889–897, 2000 Nephrol Dial Transplant 15:93–98, 2000
67. Meier-Kriesche HU, Port FK, Ojo AO, et al: Effect of waiting65. Midtvedt K, Ihlen H, Hartmann A, et al: Reduction of left ven-
tricular mass by lisinopril and nifedipine in hypertensive renal time on renal transplant outcome. Kidney Int 58:1311–1317, 2000
